On January 12, 2023, eight community members representing four ALS- and FTD-associated genes shared their experiences and priorities with more than 40 FDA staff members. This was one of ETL’s first major advocacy efforts.

​

FDA Patient Listening Sessions are informal opportunities for FDA staff to hear directly from patients and communities. The discussion and resulting summary do not constitute formal FDA guidance, policy, or endorsement of the positions presented.